GlassScriptPhysician profile
Max T Caudill
NPI 1922196435
$6,264.26
in general payments reported to CMS, 2019-2025
26 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $768 · 2021: $1,049 · 2022: $780 · 2023: $883 · 2024: $1,239 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848 · Gift: $977 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.42 |
| Gift | $977.48 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $1,948.35 | 2019-2025 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,530.30 | 2019-2024 | Trulance |
| Aimmune Therapeutics, INC. | $716.47 | 2024-2025 | Zenpep |
| Abbvie INC. | $645.42 | 2019-2023 | Creon, Viberzi, Linzess |
| Ferring Pharmaceuticals INC. | $195.61 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $158.30 | 2019-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $144.26 | 2019-2023 | Dificid |
| Allergan, INC. | $129.18 | 2019-2020 | |
| Romark Laboratories, Lc | $89.75 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $82.38 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.80 | 2019-2021 | |
| Ardelyx, INC. | $58.39 | 2024 | Ibsrela |
| Intra-Sana Laboratories | $56.47 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Pfizer INC. | $55.27 | 2023-2025 | |
| Qol Medical, LLC | $54.54 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54.16 | 2024-2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $51.01 | 2019 | |
| Janssen Biotech, INC. | $49.85 | 2023-2024 | Stelara, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $39.82 | 2022-2023 | Dupixent |
| Ethicon US, LLC | $23.51 | 2019 | |
| Lucid Diagnostics INC. | $21.63 | 2023 | |
| Vivus LLC | $20.68 | 2025 | Pancreaze |
| Celgene Corporation | $17.42 | 2021 | |
| Evoke Pharma, INC. | $16.08 | 2024 | |
| Alfasigma USA, INC. | $12.05 | 2020 | |
| Gilead Sciences, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.